A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)
- 22 February 2001
- journal article
- clinical trial
- Published by Wiley in The Prostate
- Vol. 46 (4) , 257-261
- https://doi.org/10.1002/1097-0045(20010301)46:4<257::aid-pros1031>3.0.co;2-4
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- CHEMOTHERAPY FOR HORMONE REFRACTORY PROSTATE CANCERUrologic Clinics of North America, 1999
- Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.Journal of Clinical Oncology, 1998
- Oral estramustine and oral etoposide for hormone-refractory prostate cancerUrology, 1997
- A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancerUrology, 1997
- Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.Journal of Clinical Oncology, 1994
- Inhibition of Prostate Cancer Growth by Estramustineand Etoposide: Evidence For Interaction at the Nuclear MatrixJournal of Urology, 1993
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992
- Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cellsNature, 1986